News

GeneNews has entered into an agreement allowing Eli Lilly select access to research from its osteoarthritis genomic biomarker program. Terms of the agreement were not disclosed. Heiner Dreismann,

NPS Pharmaceuticals has reported additional data from a phase 3 study supporting the efficacy of Gattex (teduglutide) in patients with parenteral nutrition (PN)-dependent short bowel syndrome (SBS). Data

Horizon Therapeutics has presented an analysis from two pivotal phase 3 trials (REDUCE-1 and REDUCE-2) evaluating its investigational compound HZT-501, a combination of ibuprofen with high-dose famotidine. The

The US Patent and Trademark Office (USPTO) has notified ExonHit of its intent to issue a re-examination certificate in connection with ExonHit’s US Patent n° 6881571 directed to

Pharmalink has been granted Japanese Patent No 4326696, for its product Nefecon. It is being developed to treat IgA nephropathy. Counterparts of the patent have been issued for

Merck KGaA has announced that group total revenues rose 2.7% in the third quarter to E1,944m from E1,893m in the year-ago quarter. The group’s operating result declined by

Ranbaxy Laboratories, an Indian major, has posted net sale of $356m for Q3, 2009, a de-growth of 18% over Q3, 2008. EBITDA was $45m, a margin of 13%

Biocon has announced a three-fold increase in profit at INR74 crore for the quarter ended 30 September, up from INR25 crore in the same period last year.The company’s

Potentia Pharmaceuticals it has entered into licensing and purchase option agreements with Alcon Research, a wholly-owned subsidiary of Alcon. The agreements provide Alcon with a license to develop